AG
GPCR icon

Artal Group’s Structure Therapeutics GPCR Stock Holding History

Artal Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-151,780
Closed -$6.51M – 123
2024
Q1 		$6.51M Buy
151,780
+65,180
+75% +$2.75M 0.17% 56
2023
Q4 		$3.53M Buy
+86,600
New +$4.96M 0.12% 62
2023
Q2 		– Sell
-75,000
Closed -$1.78M – 126
2023
Q1 		$1.78M Buy
+75,000
New +$1.76M 0.11% 82

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Artal Group's GPCR Position: Q2 2024 in Review

Artal Group sold out of Structure Therapeutics (GPCR) in Q2 2024, closing a stake of 151,780 shares — an estimated $6.51M sold.

Artal Group first reported a position in GPCR in Q1 2023 and held it in 3 quarters. The position peaked at $6.51M in Q1 2024. 166 funds tracked by Wall St. Rank hold GPCR as of Q2 2024.

  • Artal Group reported no remaining Structure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Artal Group sold 151,780 Structure Therapeutics shares in Q2 2024, an estimated $6.51M.
  • Artal Group first reported a position in Structure Therapeutics in Q1 2023 and held it in 3 quarters.
  • Artal Group's Structure Therapeutics position peaked at $6.51M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.